JBJerry Bradley

Jerry Bradley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jerry Bradley has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Fei Tang

    Miami Veterans Administration (VA) Healthcare System, Geriatric Research Education and Clinical Center (GRECC), Miami, FL 33125, USA

    2 shared publications
  • Iriana S. Hammel

    Affiliations Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, United States of America, Miami Veterans Administration (VA)Healthcare System Geriatric Research, Education, and Clinical Center (GRECC), Miami, Florida, United States of America

    2 shared publications
  • Natasha Melo Resendes

    Affiliations Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, United States of America, Miami Veterans Administration (VA)Healthcare System Geriatric Research, Education, and Clinical Center (GRECC), Miami, Florida, United States of America

    2 shared publications
  • Ana Palacio

    Department of Public Health Sciences, Miller School of Medicine at the University of Miami, Miami, FL

    1 shared publication
  • Dominique M. Tosi

    Affiliations Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, United States of America, Miami Veterans Administration (VA)Healthcare System Geriatric Research, Education, and Clinical Center (GRECC), Miami, Florida, United States of America

    1 shared publication
  • Dominique M. Tosi

    Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33125, USA

    1 shared publication

Latest Publications

  • Open Access

    Long COVID Frailty: A Comparative Analysis in a Veteran Population

    by Jerry Bradley, Elizabeth Bast, Natasha M. Resendes, Fei Tang, Victor D. Cevallos, Dominique M. Tosi, Leonardo Tamariz, Ana Palacio, Iriana S. Hammel

    Long COVID is characterized by persistent symptoms affecting one or more organ systems for at least 3 months following a SARS-CoV-2 infection. Our study aimed to examine the characteristics of frailty seen in patients with Long COVID compared to the frailty seen in aging patients with multimorbidity. This is a retrospective cohort study conducted in the Miami Veterans Affairs Medical Center (VAMC). The data used to calculate the Fried phenotype through the Johns Hopkins frailty calculator was collected from two separate clinics, a Long COVID clinic and a geriatric frailty clinic. We obtained the VA Frailty Index from VA CDW (Corporate Data Warehouse). We included 106 patients from the Long COVID clinic and 97 from the frailty clinic. Patients from the Long COVID clinic were significantly younger than those from the frailty clinic (60 ± 12.6 vs. 79.8 ± 5.8, p < 0.01). Patients with frailty in the Long COVID group experienced exhaustion (96.4% vs. 53.3%) and low activity (78.6% vs. 63.3%) at a higher rate than those in the geriatric frailty clinic. Long COVID may predispose patients to develop frailty that presents with a higher frequency of exhaustion and low activity.

  • Open Access

    The Effects of SSRIs and Antipsychotics on Long COVID Development in a Large Veteran Population

    by Jerry Bradley, Fei Tang, Dominique Tosi, Natasha Resendes, Iriana S. Hammel

    The development of Long COVID is a complex disease process that may be partially driven by neuroinflammation. Antipsychotics have been shown to exert neuroprotective effects under certain conditions. Our study aimed to determine if veterans treated with antipsychotics and/or selective serotonin reuptake inhibitors (SSRIs) for a psychiatric condition had a reduced risk of developing long-term COVID. We conducted a retrospective cohort study with two cohorts of patients based on the COVID-19 wave in which the patient’s initial infection occurred (Cohort 1: alpha/beta waves, and Cohort 2: delta/omicron waves) with stratification by age. A multivariate logistic regression model was used to evaluate the association between the use of antipsychotics and Long COVID diagnosis. In Cohort 1, antipsychotic use was associated with 43% and 34% reductions in the odds of developing Long COVID in patients aged 65 years, respectively. This association was reduced in the second cohort to 11% in patients aged <65 years and without an association over 65 years of age. SSRIs showed no benefit in either age group or cohort. Our results show that antipsychotic use for the treatment of a mental health condition was associated with a reduction in the risk of developing Long COVID, and the magnitude of this reduction varied between COVID-19 cohorts.